CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06694454
Title field or adapter rule: {'original_value': 'Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:28.105847+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Source Retrieved At: 2026-10-31T22:18:03.495925+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Non-small Cell Lung Cancer (NSCLC)", "Carcinoma, Non-Small Cell Lung", "Non-Small Cell Lung Carcinoma", "Non Small Cell Lung Cancer", "Non Small Cell Lung Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06694454"
protocolSection.identificationModule.officialTitle: "Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)"
protocolSection.statusModule.overallStatus: "SUSPENDED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Aerosolized azacytidine (AZA) via nebulizer on 3 consecutive days during the first week of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.\n\nAzacytidine will be given at escalating doses in phase 1, and at the established RP2D in phase 2.', 'name': 'azacytidine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Carboplatin (intravenous/IV), area under the serum drug concentration-time curve (AUC)=5-6 mg/mL/min based on cancer histology administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.', 'name': 'carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Paclitaxel (IV), 200 mg/m\\^2, is administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.', 'name': 'paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Durvalumab (IV) administered as a flat dose of 1500 mg on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.', 'name': 'durvalumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Cisplatin (IV), 75 mg/m\\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.', 'name': 'cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Gemcitabine (IV), 1,250 mg/m\\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.', 'name': 'gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/ Phase I Dose Escalation', '2/ Phase II Dose Expansion'], 'description': 'Pemetrexed (IV), 500 mg/m\\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.', 'name': 'pemetrexed', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.